Citadel Advisors Llc Decreased Coherus Biosciences Inc (Call) (NASDAQ:CHRS) Stake By $21.90 Million

August 13, 2018 - By Nadine Davis

Coherus BioSciences, Inc. (NASDAQ:CHRS) LogoInvestors sentiment increased to 1.49 in 2018 Q1. Its up 0.33, from 1.16 in 2017Q4. It increased, as 10 investors sold CHRS shares while 27 reduced holdings. 21 funds opened positions while 34 raised stakes. 51.20 million shares or 4.31% more from 49.09 million shares in 2017Q4 were reported. Quantbot Technologies Limited Partnership accumulated 0% or 2,209 shares. Envestnet Asset Mgmt reported 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Moreover, Trexquant Invest L P has 0.03% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 35,252 shares. Bancshares Of America De holds 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS) or 68,184 shares. Wells Fargo And Mn reported 218,448 shares. Ubs Asset Management Americas invested in 0% or 1.32M shares. Kennedy Cap Mngmt holds 88,680 shares. Federated Pa holds 1,511 shares. Deutsche State Bank Ag owns 602,970 shares or 0% of their US portfolio. Gp One Trading Ltd Partnership holds 0% or 11,925 shares. Morgan Stanley has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Macquarie Gru Ltd holds 0.01% in Coherus BioSciences, Inc. (NASDAQ:CHRS) or 420,000 shares. Ellington Mgmt Grp Incorporated Ltd Liability has invested 0.01% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Price T Rowe Md stated it has 1.49 million shares. Omers Administration Corporation has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS).

Citadel Advisors Llc decreased its stake in Coherus Biosciences Inc (Call) (NASDAQ:CHRS) by 98.73% based on its latest 2018Q2 regulatory filing with the SEC. Citadel Advisors Llc sold 1.68M shares as the company’s stock rose 49.27% while stock markets declined. The hedge fund held 21,600 shares of the health care company at the end of 2018Q2, valued at $302,000, down from 1.71M at the end of the previous reported quarter. Citadel Advisors Llc who had been investing in Coherus Biosciences Inc (Call) for a number of months, seems to be less bullish one the $1.26 billion market cap company. The stock increased 1.33% or $0.25 during the last trading session, reaching $19. About 338,764 shares traded. Coherus BioSciences, Inc. (NASDAQ:CHRS) has declined 24.26% since August 13, 2017 and is downtrending. It has underperformed by 36.83% the S&P500.

Citadel Advisors Llc, which manages about $202.23B US Long portfolio, upped its stake in Freeport (NYSE:FCX) by 3.70M shares to 4.59M shares, valued at $79.22M in 2018Q2, according to the filing. It also increased its holding in Entergy Corp New (NYSE:ETR) by 2.11M shares in the quarter, for a total of 2.17 million shares, and has risen its stake in Ishares Inc (EPP).

Ken Griffin career started in 1986 as a stocks and options trader. Soon he started a convertible bond arbitrage fund. When the market crashed in 1987, he was already rich. Today he is a billionire and manages and Citadel Investment Group is among the world’s largest hedge funds. In 2011 when many hedge funds and CTAs had poor returns, Citadel had returned over 20%, it also returned nearly 25% in 2012 and then 20+% in 2013. Citadel Advisors Llc is a Illinois-based hedge fund that was founded by Ken Griffin. It had more than $142.00 billion assets under management in December, 2014. Citadel Advisors Llc is the 30th largest hedge fund in our database. Taken from Citadel Advisors latest Adv, the fund reported to have 985 full and part-time employees. Among which 872 performing investment advisory and research functions. The hedge fund had between 11-25 clients.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Coverage

Among 2 analysts covering Coherus Biosciences (NASDAQ:CHRS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Coherus Biosciences had 3 analyst reports since March 9, 2018 according to SRatingsIntel. Maxim Group maintained Coherus BioSciences, Inc. (NASDAQ:CHRS) rating on Friday, March 9. Maxim Group has “Buy” rating and $15.0 target. The company was maintained on Friday, March 9 by Citigroup. The stock has “Buy” rating by Maxim Group on Monday, May 14.

Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company has market cap of $1.26 billion. The firm engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It currently has negative earnings. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis.

More notable recent Coherus BioSciences, Inc. (NASDAQ:CHRS) news were published by: Streetinsider.com which released: “Pre-Open Stock Movers 7/18: (CHRS) (FNKO) (GWW) Higher; (SAH) (WIN) (HCSG) Lower (more…)” on July 18, 2018, also Nasdaq.com with their article: “Coherus BioSciences to Report Second Quarter 2018 Financial Results on August 8th” published on July 24, 2018, Benzinga.com published: “51 Biggest Movers From Yesterday” on July 19, 2018. More interesting news about Coherus BioSciences, Inc. (NASDAQ:CHRS) were released by: Seekingalpha.com and their article: “Coherus BioSciences’ (CHRS) CEO Dennis Lanfear on Q2 2018 Results – Earnings Call Transcript” published on August 09, 2018 as well as Nasdaq.com‘s news article titled: “Coherus BioSciences Announces New Employment Inducement Grants” with publication date: July 25, 2018.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.